title: [Chronic infection urethroprostatit: a new look at old problem].
abstract: An open, short-term, prospective, randomized study was conducted. 114 men with chronic urethroprostatitis against chlamydial-mycoplasmal infection, mean age 41,2 +/- 0,4 years, were observed. Follow investigations were performed: PCR, microscopic examination of urethral secretions and semen, transabdominal and transrectal ultrasound examination of prostate, evaluation of indicators of local and systemic immunity. In patients with chronic urethroprostatitis, abnormal urethral secretions were dominated; according to data of ultrasound examination, changes in the prostate were registered in all patients, as well as disturbances in cellular and humoral immunity. Depending on the method of treatment, patients were divided into two groups: Group 1 received an immunomodulator Lavomax and basic treatment: azithromycin at a dose 1.0 g once a week for 3 weeks, Celebrex, physiotherapy (low-intensity laser radiation), prostate massage; and Group 2 received only basic therapy. The control group consisted of 30 healthy men. The most pronounced normalization of cellular immunity (decreased number of leukocytes, reduction of lysosomal activity, increased activity and intensity of phagocytosis, and functional reserve of neutrophils in the ejaculate), as well as normalization of lymphocyte subpopulation composition, immunoregulatory index in the peripheral blood, and levels of IgA, IgG, IL-8, INF-gamma, resolution of clinical symptoms were observed among patients in Group 1. Moreover, the rate of elimination of infectious agents was significantly higher in Group 1. Thus, the use of immunomodulator Lavomax is pathogenetically substantiated treatment for chronic urethroprostatite against chlamydial and mycoplasmal infection, which allows to include Lavomax in a comprehensive treatment of this disease.
authors.forename: O I
authors.initials: OI
authors.lastname: Letiaeva
authors.forename: O A
authors.initials: OA
authors.lastname: Gizinger
authors.forename: O R
authors.initials: OR
authors.lastname: Zigashin
mesh_terms: D002689:Chlamydia / Q000187:drug effects* / Q000502:physiology; D002690:Chlamydia Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D003131:Combined Modality Therapy; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007155:Immunologic Factors / Q000008:administration & dosage*; D007371:Interferon-gamma / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D008297:Male; D008875:Middle Aged; D009174:Mycoplasma / Q000187:drug effects* / Q000502:physiology; D009175:Mycoplasma Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D011446:Prospective Studies; D011467:Prostate / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000276:immunology / Q000382:microbiology; D011472:Prostatitis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D012661:Semen / Q000276:immunology*; D014463:Ultrasonography
chemical_list: D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007155:Immunologic Factors; D016209:Interleukin-8; D007371:Interferon-gamma